GLOBAL immunology company Argenx has welcomed the Therapeutic Goods Administration's (TGA) decision to approve Vyvgart (efgartigimod alfa) as an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.
Around 2,500-3,000 Australians are thought to have gMG, with symptoms including drooping eyelid, blurred or double vision, slurred speech, difficulty chewing and swallowing, weakness in the arms and legs, chronic muscle fatigue and difficulty breathing.
The above article was sent to subscribers in Pharmacy Daily's issue from 10 Mar 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Mar 25
